Highly Sensitised Matchability NHSBT Allocation — ESENeph MCQ

Correct answer: D — Use the biomarker for risk assessment alongside clinical AKI criteria

The best answer is “Use the biomarker for risk assessment alongside clinical AKI criteria”. Novel biomarkers may indicate early tubular stress, but routine diagnosis and management still require serial creatinine, urine output and clinical evaluation. “Diagnose stage 3 AKI directly from the biomarker result” is less appropriate because routine AKI staging remains based on creatinine and urine output “Exclude tubular stress because serum creatinine remains normal” is less appropriate because biomarkers can rise before filtration changes but are not definitive alone “Start kidney replacement therapy because the biomarker is elevated” is less appropriate because kidney replacement requires clinical indications, not an isolated biomarker “Determine the precise AKI cause directly from the biomarker” is less appropriate because they do not replace assessment of perfusion, medicines, sepsis and obstruction

Reference: NICE NG203: chronic kidney disease assessment and management: https://www.nice.org.uk/guidance/ng203/chapter/Recommendations